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INTRODUCTION
According to contemporary data very limited 
number of the developed and clinically tested mol-
ecules reaches the market. When a particular thera-
peutic effect of a tested molecule is detected, this mol-
ecule can be authorized for human use after series of 
laboratory testing on animal species (a.k.a. pre-clin-
ical phase), conducted according to the Good Labo-
ratory Practice. After this stage is successfully final-
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ized, the testing for human use in the phases of the 
clinical trials begins. The analyses show that from 
50 000 newly synthesized molecules five are used in 
humans and only one of them turns out to be effi-
cacious and safe enough to receive a marketing au-
thorization. During these tests it is being determined 
whether the therapeutic efficacy and safety are com-
parable to these of other medicinal products that are 
already implemented in the practice.  According to 
statistical data only one out of every 12 molecules 
that go through clinical trials actually reaches the 
pharmaceutical market. Having the most favorable 
conditions, the whole process from the beginning of 
the trials until the introduction of the product on to 
the market takes between seven and nine years and 
its average price is between 600 million and one bil-
lion euro without taxes and manufacturing and de-
livery expenses. At the same time, the effectiveness 
of the research and development activities (measured 
as expense for a successfully introduced molecule) is 
constantly diminishing. That is why the sponsors are 
currently looking for ways to optimize this section of 
the pharmaceutical industry.
Data of the National Institute of Health USA 
from 2013 shows that 106 649 clinical trials are be-
ing conducted in 174 countries worldwide, 27 093 of 
which are held in Europe. 
Lately, Bulgaria has been one of the high-
ly preferred countries for conduction of clinical tri-
als. According to the European Medicines Agency 
(EMA) database of clinical trials in Europe, nowa-
days (2016) 851 out of 13 530 trials are conducted in 
Bulgaria which is around 6% of the total number in 
Europe (1). One of the motives is that Bulgaria has a 
lower level of quality of health services compared to 
the developed countries. It is considered that the par-
ticipation in clinical trials can assure higher quali-
ty of treatment and access to innovative medicines. 
The investment of the international pharmaceutical 
companies for conduction of clinical trials in Bulgar-
ia is estimated to be around 200-500 million Bulgari-
an leva a year, approx. 102 – 255 million €. The analy-
sis conducted by KPMG shows that the clinical trials 
sector brings to the Bulgarian economics 77.5 mil-
lion € per year as expenses for salaries, repayment for 
the hospitals and the exploiters, legal taxes, etc. (2). 
According to the latest changes in the clinical 
trials regulation the post-authorization studies are 
two types – PASS (safety studies) and PAES (stud-
ies of efficacy). This stage is known as phase 4 of the 
clinical trials and takes place in the real clinical prac-
tice with patients. 
Post-authorization studies can be conducted 
when the medicinal product is being used according 
to the approved summary of product characteristics 
/SmPC/ in the post-authorization period. Their aim 
is identification, quantity assessment and assessment 
of the importance of the risks, linked to the use of a 
medicinal product in the clinical practice. PASS con-
duction is legally framed in Directive 2001/83 (3).
This type of studies is particularly suitable for 
obtaining new information on the prognosis, dura-
tion, and quality of life in actual conditions. The fre-
quency of both known and unknown ADRs is be-
ing studied. PASS also gives opportunity for research 
of new indications of the medicinal product as well 
as new dose regimens. Another advantage of PASS 
is the possibility to detect, find and analyze eventual 
risks in special population groups (4).
MATERIALS AND METHODS 
A questionnaire composed with the aim to as-
sess the willingness of the pharmaceutical compa-
nies in Bulgaria to conduct PASS/PAES has been car-
ried out. It describes the period before the implemen-
tation of the pharmacovigilance legislation in June, 
2012 and shows how the tendencies in the willing-
ness of companies have changed with the new legal 
requirements in the pharmacovigilance field. The 
questionnaire begins with short appeal to the pub-
lic to point out the subject and the aim of the survey, 
who conducts it and how the collected data will be 
used. The questions are presented in a funnel-shaped 
way beginning with general questions and going 
more concrete to the adopted practices for conduct-
ing PASS and PAES. The questionnaires are divided 
depending on the targeted respondents – question-
naires conducted with innovative companies and 
questionnaires conducted with generic companies. It 
consists of six questions. The received answers sketch 
the basic frame of the obligations of the companies to 
conduct post-authorization studies for safety and ef-
ficacy internationally and on a local basis as well as 
the companies’ willingness to do it.  
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The questionnaires are structured so that the 
results will be easy to code, process and analyze. De-
scriptive statistics were applied using SPSS software. 
The low responding rate and small sample size does 
not allow a comparison between the two groups. 
Subjects of the study were pharmaceutical com-
panies and representatives of marketing authoriza-
tion holders (MAH) in Bulgaria – innovative com-
panies, members of the Association of the Research-
Based Pharmaceutical Manufacturers in Bulgaria 
(ARPharM) and generic companies, members of the 
Bulgarian Generic Pharmaceutical Association (Bg-
PharmA). 16 companies participated in the survey 
– 10 innovative and 6 generic - for a period of three
months in 2015.
The questions are divided into three categories 
– requirements for conduction of PASS and PAES be-
fore 2012, conduction of PASS and PAES after 2012
internationally and in Bulgaria and importance and
influence of the results on the SmPCs.
The analysis of the results includes the require-
ments to the companies with the following criteria: 
1. Conduction of PASS and PAES.
2. Conduction of PASS and PAES for new me-
dicinal products and for those under addi-
tional monitoring.
3. Conduction of PASS and PAES for generic
medicinal products.
4. Marking with a black triangle in the SmPCs
of all medicinal products which need to be
additionally monitored after receiving mar-
keting authorization.
5. Commission for assessment of the risk/bene-
fit ratio of the medicinal products.
6. Requirements for the documentation need-
ed for receiving authorization for conducting
PASS and PAES.
7. Deadlines for receiving authorization for
conducting PASS and PAES.
RESULTS AND DISCUSSION
The participants in the survey were rather in-
novative (10) than generic (6) companies.
In the processing of the data the names of the 
companies were numerically coded from 1 to 10 
(for innovative companies) and from 1 to 6 (gener-
ic companies).
Conduction of the PASS and PAES before 
the changes in the European legislation regarding 
Pharmacovigilance 
Six of the total 10 questioned innovative com-
panies confirm to have conducted phase 4 clinical 
trials. The biggest part of them was non-interven-
tional, observational, pharmacoepidemiological and 
studies on records of morbidity. 
The questioned generic companies do not re-
port conduction of PASS and PAES before the legis-
lation changes. 
Conduction of PASS and PAES International-
ly and in Bulgaria after Implementation of the New 
European Pharmacovigilance 
Figure 1. Number of companies which participated in the 
questionnaire in a three-month period
Innovative companies Generic companies
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6
Conduction of 
PASS and PAES 
before 2012
Yes Yes No No Yes Yes Yes Yes No No No No No No No No
Table 1. Conduction of PASS and PAES in the pharmaceutical industry before 2012
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International Perspective
Currently in international perspective half of 
the questioned innovative pharmaceutical compa-
nies (5) and two of the generic ones conduct PASS 
with a total number of studies varying between 1 
and 20 studies per company. Only one of the inno-
vative companies conducts PAES. Two of the inno-
vative companies and two of the generic do not re-
port data for this type of studies in international per-
spective and two of the innovative companies have 
responded that after 2012 they have conducted such 
studies but currently they are not active. One of the 
innovative companies has stated that it is currently 
conducting PASS but without further information on 
their number. 
Three of the innovative companies share in the 
questionnaire that EMA or FDA had obliged them 
to conduct a post-authorization study of efficacy and 
two of them had to change their SmPCs due to the 
collected results. This result clearly shows that the 
implementation of the new legislation in June, 2012 
has somehow influenced the pharmaceutical compa-
nies and has led them to establish new tools for post-
marketing surveillance.
Generic companies are still more passive in the 
conduction of post-authorization studies compared 
to the innovative ones. It is also clear that the indus-
try would pursue safety studies rather than studies 
of efficacy.
Bulgaria
Nowadays, only one of the questioned inno-
vative companies has current PASS and PAES in 
Bulgaria.
Pharmaceutical Industry’s Attitude Towards 
the Conditions for Conducting PASS and PAES in 
Bulgaria and the Validity of the Obtained Data and 
Results
Four of the generic companies which partici-
pated in the survey consider Bulgaria to have good 
enough conditions for conducting PASS and PAES 
for collecting valid data. The main factors that influ-
ence the process are the type of the medicinal prod-
uct, morbidity, and the number of patients partici-
pating in the study. 
All of the innovative companies think that from 
a regulatory and logistic point of view in Bulgaria all 
the required conditions for conduction of PASS and 
PAES are present. 
Despite these declarations of opinion it is obvi-
ous that in Bulgaria the MAH representatives are not 
yet familiar and experienced enough with this type 
of studies. This is one of the reasons for the low num-
ber of PASS and PAES. 
CONCLUSION 
The conducted study on the importance, 
knowledge and willingness of the pharmaceutical 
companies in Bulgaria to conduct PASS and PAES is 
Figure 2. Number of PASS and PAES in the pharmaceutical industry after 2012
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the first one in the country which allows some con-
clusions and instructions to be made. 
The data on the willingness to conduct PASS 
and PAES show that this legal tool is not yet widely 
popularized in the activities of the regulator author-
ity and MAHs. The main limiting factors in this sec-
tor are related to the restrictive regulatory frame, es-
pecially concerning approval of new trials. 
We consider it important that MAHs share the 
opinion that in Bulgaria all the needed conditions for 
conducting this type of trials are present. Therefore, 
our country has the potential for future development 
in this sector from which healthcare professionals, 
hospitals, academia and regulatory authorities would 
benefit (5). The ongoing reforms also include an up-
grade of the legislative frame for conducting clini-
cal trials, optimization of the number of documents 
required, expansion of the administration capaci-
ty of the Bulgarian Drug Agency and Ethics Com-
mission in order to meet the requirements of Reg-
ulation 536/2014, creation of an electronic database 
which will be maintained by the BDA, enhancement 
of the interactions between the scientists, industry 
and administration. 
REFERENCES
1. www.clinicaltrialsregister.eu [accessed September
2016]
2. KPMG Bulgaria OOD – Clinical Trials in Bulgaria
– Key challenges, 2015, www.kpmg/bg
3. EMA. Guideline on good pharmacovigilance prac-
tices (GVP). GL 27 (2013). doi:EMA/876333/2011
Rev. 1*
4. Atanasov V., Kostov E., Lebanova H., Getova V.,
Popova M., Getov I., Characteristics and nature of
non-interventional studies, Science Pharmacolo-
gy, 1/2016
5. National strategy for development of clinical tri-
als and non-interventional studies in Bulgar-
ia, draft for public discussion, available on www.
mh.government.bg, last accessed 10.02.2016
6. EC. Commission Delegated Regulation 357/2014.
(2014)
7. EC. Regulation (EU) 536/2014 on clinical trials on
medicinal products for human use, and repealing
Directive 2001/20/EC
